Hypertension guidelines: A major reappraisal critically examines the available evidence

Journal of Clinical Hypertension

Volumn 12, Issue 4, 2010, Pages 229-236

  Weber, Michael A ^a,b   Materson, Barry J ^a,b  

^a SUNY Downstate Medical Center   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL PROTOCOL; CLINICAL RESEARCH; DRUG CHOICE; DRUG COST; EDITORIAL; EVIDENCE BASED PRACTICE; HEART PROTECTION; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HUMANS; HYPERTENSION; PRACTICE GUIDELINES AS TOPIC;

EID: 77952476834     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00273.x     Document Type: Editorial

References (30)

1. Mancia G, Laurent S, Agabiti-Rosei E. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009, 27:2121-2158.
2. Chobanian AV, Bakris GL, Black HR. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. JAMA 2003, 289:2560-2572.
3. Mancia G, De Backer G, Dominiczak A. Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 2007, 25:1105-1187.
4. Medical research council trial of treatment of mild hypertension: principal results. MRC working party. BMJ 1985, 291:97-104.
5. The Australian therapeutic trial in mild hypertension. Lancet 1980, 1:1261-1267.
6. The effect of treatment on mortality in " mild" hypertension: results of the Hypertension Detection and Follow-up Program. N Engl J Med 1982, 307:976-980.
7. Liu L, Zhang Y, Liu G. The Felodipine Event Reduction (FEVER) study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens 2005, 23:2157-2172.
8. Schrier RW, Eslacio RO, Esler A. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria retinopathy and strokes. Kidney Int 2002, 61:1088-1097.
9. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000, 353:253-259.
10. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007, 370:829-840.
11. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 2002, 342:145-153.
12. Nissen SE, Tuzco EM, Libby P. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study - a randomized controlled trial. JAMA 2004, 292:2217-2225.
13. Randomized trial of perindopril-based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischemic attack. Lancet 2001, 358:1033-1041.
14. Arima H, Chalmers J, Woodward M. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006, 24:1201-1208.
15. Yusuf S, Diener HC, Sacco RL. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008, 359:1225-1237.
16. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009, 27:923-934.
17. Amery A, Birkenhäger W, Brisko P. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985, 1:1349-1354.
18. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991, 265:3255-3264.
19. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992, 304:405-412.
20. Hansson L, Zanchetti A, Carruthers SG. Effects of intensive blood pressure-lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet 1998, 351:1755-1762.
21. Toumilehto J, Rastenyte D, Birkenhäger WH. Effects of calcium channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999, 340:677-684.
22. Brenner BM, Cooper ME, de Zeeuw D. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001, 345:861-869.
23. Weber MA, Julius S, Kjeldsen SE. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004, 363:2049-2051.
24. Mancia G, Messerli F, Bakris G. Blood pressure control and improved cardiovascular outcomes in the international Verapamil SR-Trandolapril Study. Hypertension 2007, 50:299-305.
25. Messerli FH, Mancia G, Conti CR. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006, 144:884-893.
26. Lewington S, Clarke R, Qizilbash N. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002, 360:1903-1913.
27. Buse JB, Bigger JT, Byington RP. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007, 99:21-33.
28. Jamerson K, Weber MA, Bakris GL. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008, 359:2417-2428.
29. Mann JF, Schmeider RE, McQueen M. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008, 372:547-553.
30. Giles TD, Materson BJ, Cohn JN. Definition and classification of hypertension: an update. J Clin Hypertens (Greenwich) 2009, 11:611-614.